Advertisement

FDA Rebukes Kim Kardashian for Morning-Sickness Drug Ad on Instagram

But pharma marketer Diclegis wins big anyway

Kim Kardashian appears at Cannes in June. Getty Images

The Food and Drug Administration has issued a warning letter informing Kim Kardashian's ad partner—the morning-sickness medication Diclegis—that her Instagram post promoting the drug was a no-no. Kardashian is pregnant with her and husband Kanye West's second child and came down with morning sickness in recent weeks.

Kardashian started taking Diclegis—evidently with great healing success—and has been pushing it on Instagram since July. She recently told an audience at the Cannes Lions International Festival of Creativity that she wouldn't do Instagram promos, but that was before the morning sickness (so cut her some slack).

"The social media post is misleading because it presents various efficacy claims for Diclegis, but fails to communicate any risk information," the FDA wrote to the 34-year-old reality TV star.

Kardashian has taken the post down from her Instagram page, which has 42.4 million followers.

The entire brouhaha appears to be a big victory for Diclegis, though, according to Treato, an Internet-based intelligence company focused on the health sector.

The Princeton, N.J.-based company, which analyzes social media and other online channels to come to its findings, concluded that Kardashian helped get Diclegis a more than 500 percent increase in digital buzz in July.

Kardashian's Instagram post alone garnered 450,000 likes. 

It appears highly likely that the Kardashian-FDA dustup will only create more brand awareness for Diclegis. Consequently, it's reasonable to assume that the 2-year-old brand, which is marketed by Blainville, Québec-based Duchesnay Inc., will see a nice uptick in sales.

Advertisement
Advertisement
Adweek Blog Network